International Conference on Oncology Nursing, Cancer Care & Radiology and Imaging September 19-20 2016 Las Vegas, USA

Dr. George Fisher is the Colleen G. Haas Professor of Medicine at the Stanford Cancer Institute. He is a graduate of Stanford University and Medical School and completed his residency and oncology fellowship there as well. His research and clinical interest is in drug development and clinical trials applied to GI malignancies. He has been the President of the California Division of the American Cancer Society and the recipient of numerous teaching and patient care awards. Dr. Fisher is the vice chair of the ECOG-ACRIN GI Committee and is the ECOG liaison to the NCI Task Force on neuroendocrine tumors. In addition he serves on the scientific and medical advisory boards of PANCAN and the Neuroendocrine Tumor Research Foundation, which he co-chairs. He is also an active ASCO volunteer and chair of the 2016 Gastrointestinal Cancers Symposium.

Clinical Trials,Cancer therapy

Dr. Benigno received his M.D. degree from the Georgetown University School of Medicine and completed his residency in Obstetrics and Gynecology at St. Vincent's Hospital and Medical Center in New York City. He completed two fellowships in gynecologic oncology, one at the Emory University School of Medicine in Atlanta and the other at the M.D. Anderson Hospital and Tumor Institute in Houston. He was a visiting professor at the University of Saigon for three years during the War in Vietnam where he set up a residency training program for young Vietnamese surgeons. From 1974 to 1982, he was on the faculty at the Emory University School of Medicine where he was the Director of Gynecologic Oncology at Emory Hospital and at Grady Memorial Hospital. Recently, Dr. Benigno founded University Gynecologic Oncology where he serves as President. He also serves as the Director of Gynecologic Oncology at Northside Hospital.

Gynecologic Oncology,Ovarian Cancer.

To be Updated

Urology,Prostate cancer etc

Jan S. Lewin, Ph.D. is a Professor in the Head and Neck Surgery Department, and Section Chief of Speech Pathology and Audiology at UT MD Anderson Cancer Center. Dr. Lewin received her undergraduate and graduate degrees from the University of Michigan and her Ph.D. from Michigan State University. She is a recognized authority on functional outcomes in oncology patients. Dr. Lewin is a regularly invited participant to national and international cancer survivorship programs and public education networks. Under her direction, the Speech Pathology and Audiology program at M.D. Anderson is recognized as the premier program for functional rehabilitation of oncology patients.

Surgical prosthetic voice outcomes following tracheoesophageal voice restoration after total laryngectomy. Alaryngeal speech rehabilitation following surgical extirpation of the larynx. Swallowing outcomes in head and neck cancer patients treated with surgery, radiation, and/or chemotherapy.

Fallone is Director of the Medical Physics at the Cross Cancer Institute, and the University of Alberta. Prior he was Faculty at McGill University and University of Texas MD Anderson Cancer Centre. He has directly supervised 80 graduate students, 25 medical physics residents, co-authored over 210 peer-reviewed articles, 90 peer-reviewed proceedings and chapters, 313 abstracts, 306/271 posters/conferences, 110 invited conferences, and 10 patents. He is recipient of $ 60M in research funds. He has received numerous international awards: most notably being Knighthood to the Order of Merit, Italy (highest recognition in Italy) for his contributions to cancer research.

Image-Guided Adaptive Radiotherapy (IGAR),Digital Electroradiography,Digital Portal Imaging and Automatic Image Registration and Verification,Inverse Treatment Planning,Conformal Therapy.

Dr. Bonnie Labdi earned her Doctor of Pharmacy degree from the University of Houston College Of Pharmacy in May of 2002. She completed two years of post-graduate residency through the University of Texas and Scott & White Hospital in June of 2004. She began working at the University of Texas M.D. Anderson Cancer Center in 2004 as a Clinical Pharmacy Specialist, focusing on the areas of hematologic malignancies, specifically lymphoma and myeloma. She remained there for over 6 years before accepting a clinical management position at a two-hospital health system located in Beaumont, Texas. As a clinical manager, she sat on many institutional committees, utilizing her leadership skills and experience in the areas of patient safety, hospital accreditation, and health care management. Most recently, she accepted a clinical specialist position at Memorial Hermann Hospital in Houston, Texas. Her primary areas of focus are in the areas of thoracic and head and neck medical oncology. She sees patients daily in clinic, working in collaboration with oncologists to formulate individualized treatment plans. Besides oncology, Dr. Labdi remains interested and active in the areas of supportive care, patient safety and quality improvement. She serves on several boards and committees of both national and international professional organizations, and is currently serving in her second year as Chairperson of the Publications Committee for the Hematology Oncology Pharmacists Association (HOPA). She has authored a book chapter and several peer-reviewed articles in the fields of oncology and supportive care. She most recently presented 3 talks at the Indo-Global Medical Summit & Expo in Hyderabad, India. She also presented a poster at the most recent World Conference on Lung Cancer annual meeting.

Oncology,Supportive care, Patient safety and Quality Improvement.

Dr. Brian Lawenda received the "Top Doctor" Award in radiation oncology by US News & World Report. He has been instrumental in bringing a new skin cancer treatment using High Dose Rate Brachytherapy to Southern Nevada. He incorporates Integrative Oncology and medical acupuncture into his practice and is the National Director of Integrative Oncology and Cancer Survivorship. Dr. Lawenda enjoys speaking to the community in regards to education on new technologies and cancer treatments that are offered at 21st Century Oncology and is involved with numerous support groups in the Southern Nevada area.

Radiation oncology, Integrative oncology and Medical Acupuncture

Dr S.Afshin Shorofi has attained his PhD from Flinders University of South Australia, where he subsequently started working as a Research Associate in Health Care for Older People. He is currently an Adjunct Research Fellow at Flinders University (Australia), and an Assistant Professor at Mazandaran University of Medical Sciences (MUMS-Iran). In addition, Afshin is the deputy head of the Traditional & Complementary Medicine Research Center and the Center for History & Ethics Studies at MUMS. Afshin is holding adjunct academic positions in two research centers at MUMS, Traditional & Complementary Medicine Research Center and Orthopedic Research Center. He is nationally well known for his publications so that he has published 17 books in the fields of Nursing, Midwifery and Medicine irrespective of his papers in peer-reviewed journals. Afshin is also serving several well-reputed journals as an editorial board member or editorial advisory board member. Afshin has been awarded prizes and honors for teaching excellence, outstanding research and overall academic achievement.

His Research interests include aged care; complementary and alternative medicine; holistic care; research issues in health; pain management; and palliative care.

Dr. Bulent Ozpolat MD has completed his PhD in Immunology at The University of Texas –Houston, MD Anderson Cancer Center and postdoctoral studies focusing on cancer biology, and nanotechnology the same center. He is current servings as an Associate professor at the Department of Experimental Therapeutics at MD Anderson cancer Center. His research focuses on identification of novel molecular targets (genes, microRNA, proteins) 2) Development of targeted-therapies for these pathways utilizing nanotechnology by delivery of therapeutic peptides, small molecule inhibitors siRNA and microRNA. Dr. Ozpolat a member of Center for Targeted Therapy, Genetics and Genomics Center, Center for Targeted Therapy, Texas-Center of Cancer Nanomedicine, and Non-Coding siRNA Center at MDACC. He serve as a reviewer for US-Congressional directed Medical research and Department of Defense (DOD)-Breast cancer and Immunology study sections, Italian health Ministry, British Cancer Foundation grants and several journals as an Editorial Board member and holds several patents published more than 50 papers, 13 reviews and 12 book chapters. His research is supported by NIH, DOD, Susan Komen, and grants from Texas Stae (CPRIT), intuitional/internally funded grants/projects.

Novel molecular targets,Immunology.

Dr.Gorijavolu Durgaprasad, completed his MBBS from Guntur Medical college and Post graduation from Osmania Medical College, Andhra Pradesh in the year 2000. He is currently working as Associate professor of Radiation Oncology and Palliative Medicine at Government Medical College and General Hospital, Anantapuramu, Andrapradesh, India. He started the Department of Pain and Palliative Medicine at M.N.J. Institute of Oncology and Regional Cancer Center, Hyderabad, India in the year 2007 with the support from INCTR, American Cancer Society and Pallium India and further he contributed a lot to the development of this department and transformed it into one of the Centres of Excellence in Palliative Medicine in India with teaching, training and research in pain management and palliative medicine.

Pain Management and Palliative Medicine